Regenerative Pathway for Knee Osteoarthritis

Pathway overview

Public reporting describes a human umbilical-cord mesenchymal stem-cell clinical translation/application pathway for knee osteoarthritis in a designated institution. Suitability depends on diagnosis, clinical severity, imaging, previous treatment and physician assessment.

Information likely required for review

• Orthopaedic or rheumatology diagnosis
• Recent weight-bearing knee X-rays
• Knee MRI where available
• Clinical grade or severity assessment
• Pain and function history
• Previous physiotherapy, injections or surgery
• Medication, infection and cancer history

What happens after submission

1. RMC checks the case summary and missing records.
2. Where a credible route exists, the case is prepared for an appropriate medical institution.
3. The hospital decides whether consultation, further testing or in-person assessment is warranted.
4. A formal plan and fee structure, if applicable, should come after medical review.

Evidence and limitations

Cell and regenerative therapies may have condition-specific evidence, eligibility rules, risks and uncertainties. Results from a study population do not predict an individual outcome. Standard treatment options should also be discussed with a qualified physician.

Public sources used for pathway identification

• Hainan government — frontier biomedical projectsOfficial public reporting identifying a knee osteoarthritis clinical translation/application project.
• Hainan science project listPublic research and real-world evidence project information.